Publicacións en colaboración con investigadores/as de Hospital de Cabueñes (18)

2024

  1. Exposure to different occupational chemicals and clinical phenotype of a cohort of patients with systemic sclerosis

    Autoimmunity Reviews

2023

  1. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial

    JAMA Network Open, Vol. 6, Núm. 4, pp. E237243

2022

  1. Anti–Polymyositis/Scl Antibodies in Systemic Sclerosis Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature

    Journal of Clinical Rheumatology, Vol. 28, Núm. 1, pp. E180-E188

2021

  1. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  2. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)

    Rheumatology (Oxford, England), Vol. 60, Núm. 2, pp. 872-880

2020

  1. Longterm efficacy and safety of monotherapy versus combination therapy in systemic sclerosis-associated pulmonary arterial hypertension: A retrospective RESCLE registry study

    Journal of Rheumatology, Vol. 47, Núm. 1, pp. 89-98

  2. Serodiscordant patients with systemic sclerosis: When antibody does not correspond to skin involvement

    Clinical and Experimental Rheumatology, Vol. 38, pp. S106-S114

  3. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

    Autoimmunity Reviews, Vol. 19, Núm. 5

2019

  1. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry

    Clinical Rheumatology, Vol. 38, Núm. 4, pp. 1117-1124

2018

  1. Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study (Clinical Rheumatology, (2018), 37, 4, (999-1009), 10.1007/s10067-017-3936-7)

    Clinical Rheumatology

  2. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study

    Clinical Rheumatology, Vol. 37, Núm. 4, pp. 999-1009

  3. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 6, pp. 849-857

  4. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group

    Rheumatology International, Vol. 38, Núm. 3, pp. 363-374

2017

  1. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE)

    Clinical and Experimental Rheumatology, Vol. 35, pp. S40-S47

  2. Clinical and epidemiological differences between men and women with systemic sclerosis: A study in a Spanish systemic sclerosis cohort and literature review

    Clinical and Experimental Rheumatology, Vol. 35, pp. S89-S97

  3. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 35, pp. S98-S105

  4. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry

    Seminars in Arthritis and Rheumatism, Vol. 46, Núm. 2, pp. 200-208